Quadcap Wealth Management LLC Has $2.06 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Quadcap Wealth Management LLC lessened its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 12.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 14,217 shares of the company's stock after selling 2,009 shares during the quarter. Quadcap Wealth Management LLC's holdings in Johnson & Johnson were worth $2,056,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of JNJ. IFS Advisors LLC increased its holdings in shares of Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company's stock worth $25,000 after acquiring an additional 100 shares during the last quarter. WealthTrak Capital Management LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $26,000. Mountain Hill Investment Partners Corp. acquired a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $29,000. Bay Harbor Wealth Management LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $32,000. Finally, Conquis Financial LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $33,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of recent analyst reports. StockNews.com raised Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, January 25th. The Goldman Sachs Group raised Johnson & Johnson from a "neutral" rating to a "buy" rating and upped their price objective for the company from $157.00 to $172.00 in a report on Wednesday, April 9th. Morgan Stanley upped their price objective on Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a report on Wednesday, April 16th. Argus raised Johnson & Johnson to a "strong-buy" rating in a report on Friday, January 24th. Finally, Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Eleven equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson has a consensus rating of "Moderate Buy" and a consensus price target of $170.88.

Johnson & Johnson Price Performance

Shares of JNJ stock traded up $1.76 on Friday, hitting $151.37. 8,045,511 shares of the company's stock were exchanged, compared to its average volume of 7,943,689. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The stock has a market cap of $364.20 billion, a P/E ratio of 22.76, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. The company has a 50 day moving average of $156.27 and a 200 day moving average of $153.94.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. On average, equities research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be issued a dividend of $1.30 per share. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.44%. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson's payout ratio is 57.84%.

Insider Transactions at Johnson & Johnson

In other news, VP Robert J. Decker sold 6,999 shares of the business's stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. The trade was a 25.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares of the company's stock, valued at approximately $2,357,552.70. The trade was a 2.60% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.16% of the company's stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.